Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLx-4090 with Statin in Hyperlipidemia
NCT00810979Phase 2Completed
- Sponsor
- Response Pharmaceuticals
- Start
- Jan 2009
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of KD026 in hyperlipidemia (3 arms), sponsored by Response Pharmaceuticals. Primary endpoint: Reduction in LDL-C at 12 weeks. Started Jan 2009; status: completed.
02
Drugs
KD026
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT00810979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00810979.